Despina Fotiou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2691012/publications.pdf

Version: 2024-02-01

117 papers	2,106 citations	361045 20 h-index	276539 41 g-index
117 all docs	117 docs citations	117 times ranked	3184 citing authors

#	Article	IF	Citations
1	Organ-specific manifestations of COVID-19 infection. Clinical and Experimental Medicine, 2020, 20, 493-506.	1.9	351
2	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	1.9	232
3	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	0.6	130
4	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. Journal of Infection, 2021, 83, 1-16.	1.7	127
5	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	2.8	103
6	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Advances, 2017, 1, 449-454.	2.5	89
7	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood, 2018, 131, 464-467.	0.6	54
8	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. American Journal of Hematology, 2017, 92, 632-639.	2.0	48
9	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers, 2020, 12, 191.	1.7	48
10	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood, 2018, 131, 1568-1575.	0.6	44
11	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	1.7	44
12	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia, 2018, 32, 2617-2625.	3.3	40
13	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal, 2018, 8, 46.	2.8	39
14	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Advances, 2021, 5, 4398-4405.	2.5	39
15	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Advances, 2019, 3, 3002-3009.	2.5	37
16	Lateâ€onset hematological complications post <scp>COVID</scp>â€19: An emerging medical problem for the hematologist. American Journal of Hematology, 2022, 97, 119-128.	2.0	36
17	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines, 2021, 9, 712.	2.1	25
18	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 234-241.	1.4	24

#	Article	IF	Citations
19	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 2020, 12, 3245.	1.7	24
20	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer Journal, 2018, 8, 102.	2.8	23
21	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 445-452.	0.2	23
22	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 19-23.	1.4	22
23	A review of the venous thrombotic issues associated with multiple myeloma. Expert Review of Hematology, 2016, 9, 695-706.	1.0	21
24	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. American Journal of Hematology, 2019, 94, 400-407.	2.0	21
25	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer Journal, 2020, 10, 109.	2.8	21
26	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	1.2	20
27	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 3-11.	1.4	18
28	Myeloma patients with COVIDâ€19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. British Journal of Haematology, 2022, 196, 356-359.	1.2	18
29	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Advances, 2019, 3, 4095-4103.	2.5	17
30	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Annals of Hematology, 2020, 99, 1251-1255.	0.8	17
31	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2020, 10, 25.	2.8	16
32	Daratumumabâ€based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	1.2	15
33	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia, 2021, 35, 1418-1427.	3.3	15
34	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. HemaSphere, 2020, 4, e381.	1.2	14
35	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer Journal, 2020, 10, 93.	2.8	13
36	Cellâ€free <scp>DNA</scp> analysis for the detection of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations in <scp>IgM</scp> monoclonal gammopathies; an update with clinicopathological correlations. American Journal of Hematology, 2020, 95, E148-E150.	2.0	12

#	Article	IF	Citations
37	Updates on thrombotic events associated with multiple myeloma. Expert Review of Hematology, 2019, 12, 355-365.	1.0	11
38	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 103-110.	1.4	11
39	Current and novel BTK inhibitors in WaldenstrÃ¶mâ€™s macroglobulinemia. Therapeutic Advances in Hematology, 2021, 12, 204062072198958.	1.1	11
40	How We Manage Patients with Plasmacytomas. Current Hematologic Malignancy Reports, 2018, 13, 227-235.	1.2	10
41	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 57-62.	0.2	10
42	Solid Organ Transplantation in Amyloidosis. Acta Haematologica, 2020, 143, 352-364.	0.7	10
43	Resveratrol activation of nitric oxide synthase in rabbit brain synaptosomes: singlet oxygen (1O2) formation as a causative factor of neurotoxicity. In Vivo, 2010, 24, 49-53.	0.6	10
44	Chromosome 1q21 aberrations identify ultra <scp>highâ€risk</scp> myeloma with prognostic and clinical implications. American Journal of Hematology, 2022, 97, 1142-1149.	2.0	10
45	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Annals of Hematology, 2019, 98, 1427-1434.	0.8	9
46	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leukemia and Lymphoma, 2019, 60, 619-628.	0.6	9
47	Long PFS of more than 7Âyears is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Annals of Hematology, 2020, 99, 1257-1264.	0.8	9
48	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e905-e909.	0.2	9
49	Treatment of Bingâ€“Neel syndrome with first line sequential chemoimmunotherapy. Medicine (United) Tj ETQq1 1 0.784314 rgBT /O	0.4	8
50	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 2021, 13, 4047.	1.7	8
51	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 259-266.	1.4	8
52	Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072210900.	1.1	8
53	Multiple myeloma: Current and future management in the aging population. Maturitas, 2020, 138, 8-13.	1.0	7
54	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	1.2	7

#	Article	IF	Citations
55	Biomarkers in AL Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 10916.	1.8	7
56	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. Blood, 2020, 136, 48-49.	0.6	7
57	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. Cancers, 2021, 13, 5057.	1.7	6
58	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Blood, 2021, 138, 2730-2730.	0.6	6
59	Formation of heme-iron complexes with nitric oxide (NO) and peroxynitrite (ONOO-) after ultraviolet radiation as a protective mechanism in rat skin. In Vivo, 2009, 23, 281-6.	0.6	6
60	Kinetics of <scp>antiâ€ŠSARSâ€ŒCoV</scp>â€‚2 neutralizing antibodies development after <scp>BNT162b2</scp> vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	2.0	5
61	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2021, 138, 3886-3886.	0.6	5
62	The current role of BTK inhibitors in the treatment of Waldenstromâ€™s Macroglobulinemia. Expert Review of Anticancer Therapy, 2020, 20, 663-674.	1.1	4
63	Ibrutinib plus rituximab for the treatment of adult patients with WaldenstrÃ¶mâ€™s macroglobulinemia: a safety evaluation. Expert Opinion on Drug Safety, 2021, 20, 987-995.	1.0	4
64	Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma. Blood, 2019, 134, 3118-3118.	0.6	4
65	Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients. Blood, 2019, 134, 4338-4338.	0.6	4
66	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2736-2736.	0.6	4
67	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. Blood, 2020, 136, 21-21.	0.6	4
68	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. Leukemia and Lymphoma, 2020, 61, 3247-3250.	0.6	3
69	Emerging drugs for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Emerging Drugs, 2020, 25, 433-444.	1.0	3
70	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. Blood, 2018, 132, 1966-1966.	0.6	3
71	Screening for Gaucher disease among patients with plasma cell dyscrasias. Leukemia and Lymphoma, 2021, 62, 761-763.	0.6	2
72	Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. Blood, 2016, 128, 4491-4491.	0.6	2

#	Article	IF	Citations
73	Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy. Blood, 2021, 138, 2708-2708.	0.6	2
74	Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality. Blood, 2021, 138, 1636-1636.	0.6	2
75	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	1.0	2
76	Discrepancies of current recommendations in breast cancer follow-up: a systematic review. Breast Cancer, 2019, 26, 681-686.	1.3	1
77	Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e320-e321.	0.2	1
78	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. Journal of Clinical Medicine, 2020, 9, 3201.	1.0	1
79	Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients. Blood, 2019, 134, 4326-4326.	0.6	1
80	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS). Blood, 2019, 134, 3126-3126.	0.6	1
81	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. Blood, 2019, 134, 5528-5528.	0.6	1
82	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. Blood, 2016, 128, 3310-3310.	0.6	1
83	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. Blood, 2016, 128, 648-648.	0.6	1
84	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. Blood, 2018, 132, 1968-1968.	0.6	1
85	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. Blood, 2019, 134, 1894-1894.	0.6	1
86	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. Blood, 2021, 138, 1668-1668.	0.6	1
87	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. Blood, 2021, 138, 2729-2729.	0.6	1
88	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. Blood, 2020, 136, 25-25.	0.6	1
89	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. Blood, 2020, 136, 33-33.	0.6	1
90	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato, 2022, 3, 188-203.	0.2	1

#	Article	IF	Citations
91	Monoclonal antibody-based therapies for WaldenstrÃ¶m's macroglobulinemia. Leukemia Research Reports, 2022, 17, 100324.	0.2	1
92	Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S76-S77.	0.2	0
93	Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e62-e63.	0.2	0
94	Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e115-e116.	0.2	0
95	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy NaÃ¯ve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S235-S236.	0.2	0
96	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S331-S332.	0.2	0
97	Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e185-e186.	0.2	0
98	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. Blood, 2015, 126, 1074-1074.	0.6	0
99	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. Blood, 2016, 128, 4500-4500.	0.6	0
100	Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Blood, 2016, 128, 4492-4492.	0.6	0
101	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. Blood, 2018, 132, 3247-3247.	0.6	0
102	In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study. Blood, 2018, 132, 2014-2014.	0.6	0
103	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study). Blood, 2019, 134, 1881-1881.	0.6	0
104	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. Blood, 2019, 134, 1877-1877.	0.6	0
105	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. Blood, 2019, 134, 1842-1842.	0.6	0
106	Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study. Blood, 2019, 134, 4124-4124.	0.6	0
107	Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study. Blood, 2019, 134, 1913-1913.	0.6	0
108	P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S104.	0.2	0

#	Article	IF	Citations
109	Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine. Blood, 2021, 138, 3802-3802.	0.6	0
110	Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy. Blood, 2021, 138, 3799-3799.	0.6	0
111	Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination. Blood, 2021, 138, 3791-3791.	0.6	0
112	De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment. HemaSphere, 2021, 5, e665.	1.2	0
113	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. Blood, 2021, 138, 3207-3207.	0.6	0
114	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. Blood, 2021, 138, 3752-3752.	0.6	0
115	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. Blood, 2020, 136, 12-12.	0.6	0
116	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. Blood, 2020, 136, 8-8.	0.6	0
117	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood, 2020, 136, 6-7.	0.6	0